Abstract 287P
Background
Nasopharyngeal carcinoma (NPC) has a high incidence among malignant tumors in China, accounting for the highest incidence of head and neck tumors. The treatment of recurrent NPC is difficult, and both the traditional in vitro cell line and PDX models have obvious shortcomings. Therefore, it is imperative to establish better disease models, to study further the mechanism of recurrent NPC, and to explore a more effective treatment method. Tumor organoids are tumor micro-organs in which stem cells are cultured in 3D in vitro. They have been verified by histopathology, molecular biology and genomics, and can retain most of the biological characteristics and tumor heterogeneity of primary tumors, which could be the best models for basic and clinical research. This study aimed to culture and identify NPC organoids using NPC biopsy and resected tissues.
Methods
Fifteen fresh nasopharygeal cancer tissue samples (diagnosed by pathology)were collected from NanFang hospital for 3D culture from June 2018 to December 2019. NPC organoids were collected, fixed with 10% formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The expression of CD133/CD44/CD47/BMI-1/EBER were detected by immunohistochemistry and in situ hybridization.
Results
1.Successful establishment of nasopharyngeal carcinoma organoid culture system. A total of 50 NPC samples were collected, and 29 organoids were successfully cultured, with a success rate of 58%. There were 16 primary NPC organoids and 13 recurrent NPC organoids. The success rate of culture of primary and recurrent NPC organoids was 47.06% and 81.25%, respectively. The success rate of culture was mainly related to tissue quality and size, specimen pollution, etc. (P= 0.002). 2. The 3D cultures were identified as NPC organoids. The pathological characteristics of HE staining of 3D NPC cultures were consistent with those of parental tumor tissues, which had typical nuclear atypia. The markers, CD133/CD44/CD47/BMI-1 and EBER, were all positivelv expressed in both 3D cultures and parent tumor tissues.
Conclusions
We have successfully established a NPC organoid model which provides a good reference for future study of the molecular mechanism of NPC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Li Gang.
Funding
Nanfang Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
34P - Clinical significance of neoadjuvant dose-dense chemotherapy for II and III stage breast cancer: A meta-analysis of published studies
Presenter: Meng chen Liu
Session: e-Poster Display Session
35P - Pathological response to weekly nabpaclitaxel and carboplatin followed by anthracycline regimen in triple negative breast cancer
Presenter: Goteti Sharat Chandra
Session: e-Poster Display Session
36P - Survival in patients with contralateral breast cancer
Presenter: Sergey Kamishov
Session: e-Poster Display Session
37P - Correlation between haematological toxicity with quality of life in breast cancer patients after first-cycle chemotherapy
Presenter: felix Wijovi
Session: e-Poster Display Session
38P - Evaluation of the prognostic value of innate immunity-related biomarkers in early breast cancer (BC)
Presenter: Veronica Martini
Session: e-Poster Display Session
39P - CSF-1R inhibitor (C019199) enhances antitumor effect in combination with anti-PD-1 therapy on murine breast cancer models
Presenter: Jiani Zheng
Session: e-Poster Display Session
40P - Molecular subtypes and imaging phenotypes of breast cancer: MRI
Presenter: Yulduz Khatamovna
Session: e-Poster Display Session
41P - Mir-223 overexpression is associated with increased expression of EGFR and worse prognosis in Indonesian TNBC patients
Presenter: Ibnu Purwanto
Session: e-Poster Display Session
42P - Impact of germline mutations on breast cancer prognosis in Kazakh population
Presenter: Dilyara Kaidarova
Session: e-Poster Display Session
50P - Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study
Presenter: Yijia Hua
Session: e-Poster Display Session